Bremelanotide: what the studies show

The approved population

Bremelanotide, also called PT-141, is the active ingredient in Vyleesi. Its US indication is acquired, generalized hypoactive sexual desire disorder in premenopausal women. Low desire must cause distress or interpersonal difficulty and have no excluded medical, medication, or relationship explanation.

Two RECONNECT trials randomized 1,267 women and studied treatment for 24 weeks. Desire and related distress improved compared with placebo. The number of satisfying sexual events did not show a significant treatment difference. Desire, distress, and sexual-event counts are distinct outcomes.

As-needed autoinjector

Vyleesi is a prefilled autoinjector for subcutaneous use as needed. The label does not describe a daily maintenance course. It calls for stopping after eight weeks when symptoms have not improved. A PT-141 research vial or nasal spray does not share the product's approval.

Risks and unanswered questions

The duration of benefit after an individual injection is not fully characterized. Nausea is common, and blood pressure can rise temporarily. The product is contraindicated with uncontrolled hypertension or known cardiovascular disease. Track desire, distress, and nausea. Sexual-event counts alone do not capture the measured benefits and risks.